



SBRI Healthcare

Small Business Research Initiative
Competition 25 AMR Briefing Event

Chaired by:
Dr Caterina Lombardo



Health
Innovation
Network

Agenda

Time	Topic	Presenters
10:00 – 10:05	Welcome and introductions	Dr Caterina Lombardo
10:05 – 10:20	Introduction and overview of the SBRI Healthcare Programme and Competition 25	Dr Michelle Edge
10:20 – 10:40	Antimicrobial Resistance (AMR) - overview of the priority areas	Professor Matt Inada-Kim
10:40 – 11:00	Q&A session	All
11:00 – 11:10	The Health Innovation Network	Dr Raasti Naseem
11:10 – 11:20	The application and assessment process	Dr Danilo Villanueva Navarrete
11:20 – 11:50	Q&A session	All
11:50 – 11:55	Closing remarks	Dr Caterina Lombardo

Housekeeping

- Thank you all for taking the time to join
- Feel free to ask questions in the Q&A box as we go along, and we will answer them in the Q&A sessions
- Please flag any technical issues in the chat
- The slides and the recording will be uploaded on SBRI Healthcare website
- For further enquiries: sbri@lgcgroup.com

Overview of SBRI Healthcare

Presented by:
Dr Michelle Edye

About SBRI Healthcare

- Pan-government, structured process enabling the public sector to engage with innovative suppliers
- AAC programme managed by LGC Group & supported by the Health Innovation Network (HIN)



Improve patient care



Increase efficiency in the NHS




Enable the NHS to access new innovations through R&D that solve identified healthcare challenges and unmet need



Bring economic value and wealth creation opportunity to the UK economy

Funding landscape




NIHR | National Institute for Health Research



Health Innovation Network





**Supported by the
Health Innovation Network**

The Health Innovation Network

A
connected
'Network of
Networks'





Themed competitions to address identified unmet NHS challenges at early and late stage of innovation



- Particularly suitable for SMEs, but any size of businesses is eligible
- Other organisations from public and third sectors (including charities) are eligible as long as the route to market is demonstrated
- Based anywhere in Europe



At early stage of innovation the Programme has a phased development approach

- Phase 1, feasibility project (6 months, up to £100K, NET)
- Phase 2, development project (12 months, up to £800K, NET)

Early-stage innovations - Phase 1 and Phase 2

What this is for

Innovation type -

Digital health & AI, medical devices, in-vitro-diagnostics, behaviour interventions and service improvements



What this is not for

Innovation type -

N/A

Entry point -

Phase 1 - no set entry point

Phase 2 - open only to successful Phase 1



Entry point -

Phase 1 - N/A

Phase 2 - new proposals which haven't been through Phase 1

Scope -

Phase 1 - technical/commercial feasibility

Phase 2 - prototype development/clinical evidence



Scope -

Proposals that do not address the specific competition brief

Phase 1 and Phase 2 expected exit points



Phase 1

Demonstrate the technical and commercial feasibility of the proposed technology:

- Feasibility technical study
- Market validation
- Business plan
- Clinical partners identified
- Evidence generation plan for adoption
- Development of PPIE strategy
- Health inequalities impact assessment
- Plan to support the NHS to achieve its net zero ambitions



Phase 2

- Minimal Viable Product developed
- Early clinical evidence gathering to demonstrate accuracy (and safety)
- Commercialisation strategy: business model, price strategy and plan for next funding stream
- Health economics
- Evidence gathered towards regulatory documentation
- Implementation plan for adoption
- Steps towards the carbon neutral strategy and objectives for the NHS
- Strong involvement and engagement with patients and public, steps towards equality, diversity and inclusion and commitment to reduce health inequalities

Portfolio snapshot



333
supported



£150m+
Total invested

Portfolio snapshot

Musculoskeletal Disorders

Integrated care & social care

Dentistry, Oral Health & Oral Cancers

Urgent & Emergency Care

Stroke

Cardiovascular Disease

Inequalities in Maternity care

Child Health

Autism & Learning Disabilities

Sustainability & Net Zero

Early diagnosis of cancer

NHS Reset and Recovery

Prevention of CVD

CYP mental health

Respiratory diseases



Portfolio snapshot



108

Companies with commercial revenues

73



products exported



93

Companies with sales in the NHS

353

IP granted



£98m+

revenue generated



£719m+

Private investment leveraged

2,874

jobs created/retained



2,515

New collaborations established

>11.2m

patients involved through sales and trials



30,773

Sites accessed through trials or sales





Support



PRE-COMPETITION	Launch webinars, drop-in sessions and clinics
IN-COMPETITION	NICE Metatool Webinar support on: what a good application looks like, Patient and Public involvement, commercialisation, IP, finance, impact, tailored sessions etc
IN-PORTFOLIO	Investment readiness programme, showcase events, webinar series on regulatory landscape, roadmap to the NHS, health economics, DTAC, peer to peer support, women in Healthtech Leadership programme
IMPACT	Case studies, annual survey and annual report



Innovate UK




Innovate UK Knowledge Transfer Network



Innovate UK EDGE



NICE National Institute for Health and Care Excellence



Accelerated Access Collaborative

Health Innovation Network



Phase 1 competition: Antimicrobial Resistance (AMR)



Challenges

- Point of care diagnostics, monitoring, and susceptibility testing
- Prescribing decision support and risk stratification
- Novel care delivery methods
- Infection prevention and control (IPC)

[AMR Web Page](#)

[AMR Challenge Brief](#)

[Phase 1 – Guidance for Applicants](#)



Antimicrobial Resistance (AMR) - priorities


Presented by:
Professor Matt Inada-Kim



**Health
Innovation
Network**



NHS Landscape



Infection system redesign



Clinical Pathways



TheKingsFund > nuffieldtrust
Public satisfaction with the NHS and social care in 2021

Satisfaction with GP services fell from 68% to 38%
 Satisfaction with A&E services fell from 54% to 39%

What are the challenges?



Prevention (& preparation)




linked data



Point of Care tests

Standardised rate of Infections admissions per 10,000 population in 2016-17			
	Episodes	Deaths	Bed days
1 Most deprived	438	38	4,488
2 More deprived	353	31	3,589
3 Mid quintile	303	26	2,963
4 Less deprived	271	23	2,635
5 Least deprived	243	20	2,301




Poorest going to A&E more than 300 times a year 'because they have nowhere else to turn', say Red Cross

How can we innovate?
 What are the opportunities?


The NAP's key priorities

Will require a patient centred, coordinated response across/within all NHS organisations and Must be Clinically Led and Implemented




Optimal management of both Infection & AMR

the importance of balance




Optimising processes in Sepsis
Early Recognition
Timely Escalation
Expedient Intervention
Reliable antibiotic reviews
Escalation



Benefits of expedient treatment Antibiotic resistance


Do you give antibiotics just in case?



Optimising processes in AMR
Treat appropriately
Start Smart then Focus
Reliable antibiotic reviews
De escalation
Avoid/remove catheters

What is the incidence & trajectory of infections?


Top reasons for Emergency admission



Top reasons for ED attendance


SNOMED-CT Description	Total
ALL	10,199,364
Urinary tract infectious disease	257,373
Sprain of ankle (disorder)	212,361
Lower respiratory tract infection	209,747
Cellulitis	151,790
Open wound of finger	144,683
Coronavirus disease 19 caused by severe acute respiratory syndrome coronavirus 2	139,645
Acute coronary syndrome	139,044
Traumatic brain injury with no LOC	138,976
Upper respiratory infection	125,108

Proportion of Total NHS Hospital Deaths



And yet 'infection' budgets for improvement are a tiny fraction of workstreams for established specialty conditions

Infections cause half of total bed days



How can we integrate/bring services together?

How can we use the opportunities to improve care?

How can we improve access for optimal infections management in community settings?

Increasing growth of those susceptible to infections

- 3.9% of the population are now classified as immunocompromised

[https://www.thelancet.com/journals/lanepi/article/PIIS2666-7762\(23\)00166-7/fulltext](https://www.thelancet.com/journals/lanepi/article/PIIS2666-7762(23)00166-7/fulltext)

- Growing use of complex immunosuppressive treatments



<https://pubmed.ncbi.nlm.nih.gov/18793004/>

- Increased success at keeping those with severe, chronic illnesses alive

Over a 36-year period, the overall Standardised mortality in the first and last decades were 12.60 and 3.46 respectively

CMI CLINICAL
MICROBIOLOGY
AND INFECTION

ESCMID EUROPEAN SOCIETY
OF CLINICAL MICROBIOLOGY
AND INFECTIOUS DISEASES

Roy F. Chemaly  


[Open Archive](#) • Published: July 10, 2021 • DOI: <https://doi.org/10.1016/j.cmi.2021.07.003>

Transparency
declaration

With greater advances in medicine, more patients with immunocompromising conditions are living longer [[1]]. In parallel, patients with terminal diseases are being treated with immunosuppressive therapies to extend their lifespan and cure their underlying disease [[2],[3]]. Overall, it is estimated that immunocompromised patients, such as those with asplenia, human

INFECTION


Prevention Preparation



Presentation

Infection symptoms


- Fever, Confusion
- RTI= Cough, Shortness of breath
- UTI= Frequency, dysuria, loin pain
- Cellulitis= Red tender skin
- Ulcer= New redness or discharge
- Abdominal pain, diarrhoea, vomiting



Acute care

- Timely appropriate access
 - Capacity, workforce
- Clinical Assessment
 - Training
 - Red flags/Soft signs
 - NEWS2, PEWS, MEWS
- Standardised Clinical Pathways
 - Decision support
- Tests
- Treatment
- Monitoring
- Safety netting
- Linked Electronic systems

Outcomes



Interlinked Data


Education

Empowerment


Vaccination

Optimal disease Mx

Infection Systems Redesign



The growth of infection admissions over time



Evaluation of winter pressures on general practice in Manchester: a cross-sectional analysis of nine GP practices

Sinead Millwood, MBBS, DFRSH^{1*}, Peter Tomlinson, BSc(H)², Jon Hopwood, MB ChB, BSc, FRCGP, DFFP^{1,4†}

Any winter pressures strategy should target both respiratory A&E self-referrals. Transferring 50% of self-referrals in Manchester would achieve a £2.3 million cost saving

More people dying of pneumonia in north of England than south as NHS report reveals problems in care

UP has more deaths than south of England, analysis of GP records shows, says NHS

Healthcare Daily September 11, 2016 10:00 AM



WORKFORCE

Socioeconomic deprivation and accident and emergency attendances:


cross-sectional analysis of general practices in England

There were more than twice as many A&E attendances in England for the 10% of the population living in the most deprived areas (3.1 million), compared with the least deprived 10% (1.5 million)

	Episodes	Deaths	Bed days	Deaths (Odds Ratio)
1 Most deprived	438	38	4,488	1.00
2 More deprived	353	31	3,589	0.80
3 Mid quintile	303	26	2,963	0.67
4 Less deprived	271	23	2,635	0.60
5 Least deprived	243	20	2,301	0.51


Referrer- call handler, 111/ambulance (DoS), GP reception, Care/nursing home, community nursing, mental health, social care

Single point of access for **urgent advice with suspected infections** at community deterioration



Acute Infection hubs - Clinical Pathway & Research opportunities

REFERRAL SOURCES
At risk patient
GP reception
111
Ambulance
Pharmacies




Addressing all ages, all infections


*** Infection symptoms**

Fever, Tiredness, altered behaviour
Cough +/- sputum,
Shortness of breath,
Sore throat,
Lethargy

- RED FLAG SYMPTOMS**
- Breathlessness
 - At rest
 - Can't complete sentences
 - On minimal exertion
 - Severe Fatigue
 - New confusion or drowsy
 - Chills/Rigors
 - Collapse or Faint
 - Stopped passing urine
 - Chest pain that does not settle
 - Coughing up a lot of blood
 - Change in colour or darkening of lips
 - Rash that does not fade when pressed



Acute respiratory infections (ARI) HUB



The hub model provides

- **Improved Access & capacity**- for the assessment, diagnostics, treatment, monitoring and coordinated care provision in acute community ARI patients- including those with COVID
- Focal point for Prevention strategies and reduced nosocomial infections
- Optimal infections management (stewardship through SOPs, POC tests; reduced nosocomial risk)
- Same Day Urgent Integrated care coordinating pathways reducing inappropriate admissions/attendances
- Supporting demand for same day urgent community assessments and enabling GP focus on chronic complex illness, high intensity users and prevention.

What tests do we need?

Rapid (15 min) POC Diagnostics

- Patient (Hx / Ex)
- Physiology
- **Tests**
- Treatment

- **DIFFERENTIATE VIRAL/BACTERIAL INFECTION** e.g. Mx proteins
- **PATHOGEN IDENTIFICATION** e.g. BCx -> Pn/Leg Ag, Metagenomic DNA, PCR
- **ILLNESS SEVERITY** e.g. CRP / WBC -> PCT, ProADM

Differentiating a well looking ill patient from an ill looking well one...


No single gold standard 'sepsis' test or tool.

...and who will pay for them?

What are the @home treatment options for moderate-severe infections?



Can they reduce LoS?
Can they prevent admission?



How can we improve the

- **Accessibility**
- **Efficiency**
- **Effectiveness**

of these treatment options?

Acute respiratory infection hubs




December 2022 - March 2023



363
ARI Hubs

Population coverage

Reported in February 2023



£48 Average cost per appointment

£28 High volume hubs Average cost per appointment



Over a 16 week time period

729,808

people seen in an ARI hub

compared to

450,000

people attended ED with an ARI

Impact

@mattinadakim

61% Agree/strongly agree that ARI hubs

Reduced ARI pressures on ED attendance

83% Agree/strongly agree that ARI hubs

Reduced ARI pressures on primary care

87% Agree/strongly agree that ARI hubs

Improved same day access to urgent care

without a hub, it is estimated that up to half of people seen would have gone to an emergency department and up to half to general practice

Areas with the highest rates of ARI hub activity had the greatest reductions in ARI ED attendees




Evidence based reframing of antibiotic treatment urgency

New National Sepsis guidance

With thanks to M.Singer & J.Bion



1. How sick is the patient?
2. **What is the likelihood of infection?**
3. Appropriate treatment urgency
4. Hospital centric guidance-
what about the community?



NEWS2 0 - 4

If infection is unlikely do not treat

You have time

Send tests

Use Clinical Judgement

Escalate to next level if concerned

Certainty of bacterial infection
 v
Illness severity


	Vital signs: NEWS-2 'Physiology first'	0	1-4
	If Clinical/carer concern, continuing deterioration, neutropenia or lab evidence of organ dysfunction (incl. lactate), upgrade actions to next NEWS2 level		
Initial (generic) actions	Monitoring and escalation plan	Standard observations	<ul style="list-style-type: none"> Registered nurse review <1 h Obs 4-6 hrly if stable. Escalate if no improvement
	Initial treatment of precipitating condition	Standard care	< 6 hr
Likelihood of infection & actions	Unlikely	Standard care	Review daily and reconsider infection if diagnosis remains uncertain
	Possible	Review at least daily	< 6 h <ul style="list-style-type: none"> Source identification & control plan documented.
	Probable or definite	< 6 h <ul style="list-style-type: none"> Diagnostic tests & R plan 	< 6 h <ul style="list-style-type: none"> Microbiology tests Antimicrobials: administer or revise Source identification & control plan. D/w ID/micro if uncertain, & review

NEWS2 5 or more

If infection is unlikely, do not treat

If infection is possible or probable then treat

Do not delay where there is shock or NEWS2 7 or more



	Vital signs: NEWS-2 'Physiology first'	5-6	≥ 7
Initial (generic) actions	Monitoring and escalation plan	<ul style="list-style-type: none"> • Obs hourly. • Review <1 hr by clinician competent in acute illness assessment • Escalate if no improvement 	<ul style="list-style-type: none"> • Obs every 30 mins. • Review <30 min by clinician competent in acute illness assessment. • Senior doctor review <1 hr if no improvement: refer to Outreach or ICU
	Initial treatment of precipitating condition	< 3 hr	< 1 hr
Likelihood of infection & actions	Unlikely	Review daily and reconsider infection if diagnosis remains uncertain	
	Possible	< 3 h: <ul style="list-style-type: none"> • Microbiology tests • Antimicrobials: administer or revise • Source identification & control plan documented. 	< 1 h: <ul style="list-style-type: none"> • Microbiology tests • Antimicrobials: administer or revise (broad-spectrum if causative organism uncertain).
	Probable or definite	< 6h <ul style="list-style-type: none"> • Source control initiated 48 – 72 h <ul style="list-style-type: none"> • Review antimicrobials with ID/micro/senior clinician 	< 3 h <ul style="list-style-type: none"> • Source identification 3-6 h <ul style="list-style-type: none"> • Source control initiated according to clinical urgency 48 – 72 h: <ul style="list-style-type: none"> • Review antimicrobials with ID/micro/senior clinician

Suspected acute respiratory infection in over 16s: assessment at first presentation and initial management

Matt Inada-Kim 25.7.24



NICE guideline [NG237] Published: 31 October 2023 Last updated: 16 November 2023


Research recommendations

NEWS2 for ARI assessment in community settings

Point of Care tests

Antimicrobial usage

National Ambulance ARI assessment tool



Article
Acute Respiratory Infection Hubs: A Service Model with Potential to Optimise Infection Management

Sarah Jawad ¹, Anna Buckingham ², Charlotte Richardson ^{1,2}, Aoife Molloy ^{2,3}, Bola Owolabi ^{2,4} and Matt Inada-Kim ^{2,5,6,7*}

The impact of ARI hubs

- ? Primary care, ED attendances
- ? Hospital Admissions
- ? Deaths, Length of stay, costs
- ? Patient satisfaction




- Primary care- chronic/prevention and acute episodic
- Reduced avoidable ED attendances
- Reduced Hospital Admissions
- Reduced Deaths, Length of stay, costs

- Broadening of conditions to other acute syndromic presentations
- Expansion into chronic complex disease management

AMR Phase 1 Funding Competition

1. Novel care delivery methods e.g. infection hubs using linked data management systems
2. Optimising use of antimicrobials e.g. Clinical decision support tools
3. POC diagnostics, monitoring and susceptibility testing – LRTI, UTI, Sepsis, Surgical site
4. Infection prevention and control





Q&A session- please do fire up any questions you might have in the Q&A box



Health Innovation Network Support

Presented by:
Dr Raasti Naseem




**Health
Innovation
Network**



Health Innovation North East and North Cumbria (HI NENC)

**Dr Raasti Naseem
Programme Manager – Economic Growth**

What are the Health Innovation Networks?



- 15 HINs across England
- Established by NHS England in 2013 to spread health innovation at pace and scale
- Improving health and generating economic growth
- Innovation arm of the NHS

Commissioned by

NHS




Office for
Life Sciences

We work locally and nationally

Our area

NHS North East and North Cumbria Integrated Care Board (ICB)

NHS
North East and
North Cumbria



Identify innovation & improvements to specific problems. Healthcare, academic or business setting. Creates an innovation pipeline

Empower innovators to further their ideas and connect with the right stakeholders

Advance the uptake and spread of innovation and improvements by delivering national programmes and initiatives within the NHS and social care.

Nationally, our goal is to bring individual HINs together

**Drive
Change**

What do we do at HI-NENC?



- Focus on 6 key areas
- **Identify, evaluate, adopt, disseminate** transformative innovation
- Facilitate collaborations and partnerships
- ****Innovation pathway****



HIN support to applicants

- Expertise across the AMR landscape
- Application review and development advice
- Awareness of current trials/ studies, emerging innovation and possible gaps
- Stakeholder engagement
- Innovation review - understand the unmet need and help required to build the portfolio of evidence
- Spread and adoption toolkit to enable us to help you plan for future commercialisation

Get in touch!

- What happens next?

<https://healthinnovationnenc.org.uk/>

Enquiries@healthinnovationnenc.org.uk

Raasti.Naseem@healthinnovationnenc.org.uk


Thank you


Questions?

Assessment process and how to apply

Presented by:
Dr Danilo Villanueva Navarrete

Phase 1 and Phase 2 assessment process




Problem identification & articulation of clinical need
NHS Long Term Plan,
Strategic papers, KOLs, Industry, HINs, Patients



NHS
Patients
NHS access
Sales

The assessment criteria

1. How well does the application address the challenge brief and does the proposed solution benefit patients, the NHS and/or Social Care Sector and the wider market? 20%
2. Are the project plan, deliverables and risk mitigation strategy appropriate? 15%
3. Is the product innovative, will it have a competitive advantage over existing and alternative solutions and are the arrangements surrounding the use and development of Intellectual Property appropriate? 15%
4. Does the proposed project have appropriate commercialisation and implementation plans? 15%
5. Does the proposed innovation have potential to enhance equity of access and does the project include consideration towards patient and public involvement? 10%
6. Does the proposed technology have potential to contribute to net-zero emission? 5%
7. Do the host organisation and project team appear to have the right skills and experience to deliver the project? 15%
8. Are the costs justified and appropriate? 5%

Phase 1 competitions: Antimicrobial Resistance



Key dates

Competition launch	17 th July – 28 th August 2024
Assessment	September-October 2024
Selection Panels	November 2024
Contract awarded	January 2025



Application process – www.sbrihealthcare.co.uk

Home Contact us [Application Portal Login](#)

About us [Competitions](#) News Impact NHS Cancer Programme Innovation Open calls

Funded by:
Accelerated Access Collaborative

[Open Competitions](#) Closed Competitions How to apply FAQs

SBRI HEALTHCARE
Apply for funding through SBRI Healthcare competitions

05 JULY, 2024
Competition 26 - Stroke

[Read more >](#)




**Health
Innovation
Network**




Competition documents

- 1 Competition launch
17th July 2024
- 2 Competition close
28th August 2024 1:00pm
- 3 Selection Panel
November 2024
- 4 Contract start
January 2025


-  Invitation to Tender (ITT)
Challenge Brief
Template Application Form
Finance Form
Development Agreement



Application Portal Login



Links to: Guidance for Applicant – Phase 1
Portal Guidance & FAQs



The Research Management System (RMS) Portal

Programme Management Office

Research Management System



Existing Users

Please log in to access your account.

Email

Password

Login

[Forgot Password?](#)

New users

Please register with us to create your account using your **institutional** email address.

Please note that all new users require validation by the Programme Management prior to receiving access to the system. We will endeavour to complete this validation process as soon as possible (within standard working hours) following completion of your initial registration

Register

[System Help](#) 

Programme Management Office

Research Management System

Dr [REDACTED]

Welcome to Programme Management Office Research Management System, Dr [REDACTED]

Home

[My Applications](#)

[My Co-applications](#)

[My Grants](#)

[My Research Outputs](#)

[My Reviews](#)

[My Tasks](#)

[Manage My Details](#)

[Contact Us](#)

[Logout](#)

[System Help](#) 

Please update your CV.

Your CV was last updated on 30 April 2020.

Please check that your CV details are up-to-date as it assists us when assessing grant applications and assigning external reviewers. To update your CV, go to [Manage My Details](#).

New Grant Application

To apply for funding from one of our grant streams click [here](#).




Programme Management Office

Research Management System

Mr [redacted]

Logged in as Console account - Mr Ken Middleton - ken.middleton@nihr.ac.uk do not use for testing as an applicant or reviewer


- Home
- New Application
- My Applications
- My Research Outputs
- My Tasks
- Manage My Details
- Contact Us
- Logout
- System Help 

Open funding rounds

The table below shows all the funding rounds currently accepting applications.

Click **More info** to view additional information about each funding round.
Click **Apply** to access the online application form for the type of grant you wish to apply for.

Grant Type	Funding Round	Submissions Window	Closing Date	more info	Apply
SBRI Phase 1 SBRI Healthcare, an NHS England & NHS Improvement initiative that aims to promote UK economic growth whilst addressing unmet health needs and enhancing the take up of known best practice. SBRI supports a programme of competitions inviting companies to come forward with their ideas on novel MedTech and digital innovations that can address specific NHS challenges.	SBRI 17 Phase 1 - Urgent and Emergency Care		27 August 2020 BST	More info	Opening 15/07/2020





Urgent and Emergency
Care

26817

[Details...](#)

✓ Introduction

Section 1: Application
Summary

Section 2: Company
Details

Section 3: Plain
English Summary

Section 4: Project Plan

Section 5: Team

Section 6: Budget

Section 7: Supporting
information

Section 8:
Administrative contact
details

Section 9: Validation
Summary

Introduction

[Previous](#)

[Next](#)

[Save](#)

[Save And Close](#)

There are a number of **online guidance prompts** (marked as a ?) available to you throughout the online form to help you when completing an application. It is **strongly advised** that you also read the relevant **Guidance for Applicants** before completing your application.

Please keep the use of acronyms to a minimum. Only use acronyms where a term is used frequently throughout the application. If you do choose to use an acronym, do not assume that the reader knows what it means, and be sure to define it when first used.

You are strongly advised to structure the longer sections of the application form (particularly the Project Description and Breakdown) in such a way that they can be read easily by reviewers. **The use of long passages of dense, unstructured text should be avoided.**

Schematics, tables, illustrations, graphs, and other types of graphics can be embedded to clarify the project plan but they should not clutter the central narrative. Images do not count towards the overall word count but inclusion of them to overcome word limits is not permitted. Images may only be included within the Project description and breakdown. **Images included in other sections will be removed from the application and not seen by reviewers.**

Members of the project team will need to be invited through the RMS *via* email to participate as team members, after which they must both **confirm and approve their participation**. Please ensure that all team members invited to collaborate on this application have confirmed their involvement and approval of the application form content before submission.

Although confirming and approving an application can be done at any time during the submission of an application, you are strongly advised to do this well in advance of the deadline.

If you have any queries with your application, you can contact the SBRI Healthcare Programme Management Office on 020 8843 8125 or SBRI@LGCGroup.com.



Dr [redacted]

[Home](#)

[My Applications](#)

[My Co-applications](#)

[My Grants](#)

[My Research Outputs](#)

[My Reviews](#)

[My Tasks](#)

[Manage My Details](#)

[Contact Us](#)

[Logout](#)


[System Help](#) 

My Co-applications

You have 1 co-application awaiting submission.

To view more details please select an application from the grid below.

Reference	Title	Main Applicant	Role	Confirmed	Last Updated	Application Status	
26808		Dr [redacted]	Co Applicant	N	14/07/2020 14:19:28	Pre-Submission	



Dr [redacted]

[Home](#)

[My Applications](#)

[My Co-applications](#)

SBRI Phase 1
Ref: 26808

Details

[My Grants](#)

[My Research Outputs](#)

[My Reviews](#)

[My Tasks](#)

[Manage My Details](#)

[Contact Us](#)

[Logout](#)

[System Help](#) 

As a co-applicant you must first 'Confirm' your participation before the application can be submitted by the Lead Applicant. Please ensure your CV is up to date (this can be updated in the manage my details section).

Lead Applicant Dr [redacted]
Title
Reference 26808
Status Pre-Submission
Total Requested £0.00

Organisation
Grant Type SBRI Phase 1
Funding Round Urgent and Emergency Care
Closing Date

Participants Co Applicant

- [redacted]
Confirmed participation
Submission approval status
- Ms [redacted]
Confirmed participation
Submission approval status
- Dr [redacted]
Confirmed participation
Submission approval status

Role: Co Applicant
Actions shown below are for your involvement as a Co Applicant

Confirm your participation

I have read the terms and conditions under which grants are awarded, and, if this application is successful, I agree to abide by them. I shall be actively engaged in the day-to-day management and control of the project and this proposal.

Reject your participation

If you do not wish to participate in this application or think that this approach was in error please click the reject button below. This will send an email to the lead applicant and remove you from the application.





Q&A session- please do fire up any questions you might have in the Q&A box



**SBRI Healthcare will hold a Q&A session for any additional questions applicants might have during the application process
on 8th August 2024
from 14:00 to 15:00**

Registration on

<https://www.eventbrite.co.uk/e/sbri-healthcare-competition-25-phase-1-qa-session-tickets-952708766567>

**To be kept up to date about all our initiatives, please subscribe to our newsletter adding your details at the bottom of this page:
https://sbrihealthcare.co.uk/about-us#subform_section**



**Health
Innovation
Network**



SBRI Healthcare

LGC Ltd

Grant Management Group

15 Church Street

Twickenham TW1 3NL

Contact us for advice and specific guidance:

T 020 8843 8125



sbri@lgcgroup.com



<https://www.sbrihealthcare.co.uk>



<https://www.linkedin.com/company/sbri-healthcare>



<https://twitter.com/sbrihealthcare>



**Health
Innovation
Network**